No Result

View All Result

No products in the cart.

2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑

Home StudyGraphics

#VisualAbstract: Ciprofloxacin is Noninferior to Aminoglycoside–Ciprofloxacin for Treatment of Bubonic Plague

byAstrid BradshawandAlisha Yi

August 21, 2025

in StudyGraphics

Reading Time: 1 min read

#VisualAbstract: Ciprofloxacin is Noninferior to Aminoglycoside–Ciprofloxacin for Treatment of Bubonic Plague

Click here to read this study in NEJM.

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Ciprofloxacin is non-inferior to aminoglycoside-ciprofloxacin for bubonic plague treatment

Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum β-lactamase-producing Escherichia coli in the community

Patient Basics: Plague (Yersinia Pestis)

Schrödinger Halts CDC7 Inhibitor After Two Patient Deaths

RelatedReports

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription

All Specialties

Ciprofloxacin is non-inferior to aminoglycoside-ciprofloxacin for bubonic plague treatment

August 28, 2025

Publication of pneumonia antibiotic guidelines changed prescribing trends

Infectious Disease

Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum β-lactamase-producing Escherichia coli in the community

December 18, 2019

Health A to Z

Patient Basics: Plague (Yersinia Pestis)

November 30, 2014

HOSPITAL score predicts risk of 30-day potentially avoidable readmission to hospital

GSK and Hengrui Pharma Forge $500 Million China Collaboration, Including PDE3/4 Inhibitors

Incidental findings common with breast imaging, often benign

Extended aromatase inhibitor therapy reduces breast cancer recurrence in postmenopausal women

#VisualAbstract: Vepdegestrant Increased Progres-sion-Free Survival in Advaced Breast 2m TM Cancer with ESR1 Mutations

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

#VisualAbstract: Ciprofloxacin is Noninferior to Aminoglycoside–Ciprofloxacin for Treatment of Bubonic Plague

Ciprofloxacin is non-inferior to aminoglycoside-ciprofloxacin for bubonic plague treatment

Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum β-lactamase-producing Escherichia coli in the community

Patient Basics: Plague (Yersinia Pestis)

Schrödinger Halts CDC7 Inhibitor After Two Patient Deaths

GSK and Hengrui Pharma Forge $500 Million China Collaboration, Including PDE3/4 Inhibitors

RelatedReports

Ciprofloxacin is non-inferior to aminoglycoside-ciprofloxacin for bubonic plague treatment

Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum β-lactamase-producing Escherichia coli in the community

Patient Basics: Plague (Yersinia Pestis)

GSK and Hengrui Pharma Forge $500 Million China Collaboration, Including PDE3/4 Inhibitors

Extended aromatase inhibitor therapy reduces breast cancer recurrence in postmenopausal women

#VisualAbstract: Vepdegestrant Increased Progres-sion-Free Survival in Advaced Breast 2m TM Cancer with ESR1 Mutations

2MM+ All Access

Recent Reports

The medical literature, distilled daily.

Membership benefits